Loading... Please wait...
Sort by:

therapy-trends-jpg.jpg
Therapy Trends
r
eports deliver critical and unbiased intelligence derived from in-depth interviews with the world’s foremost thought leaders on the current and future treatment landscapes in major disease areas. Research is focused on the major battlegrounds for market share and answers critical business questions about potential product positioning and competitiveness. Through continuous monitoring and frequent re-engagement with stakeholders, the FirstWord Therapy Trends analyst team delivers quarterly updates with each report ensuring insights remain current and relevant.

  • NSCLC: KOL Insight [2017]
    Learn More NSCLC: KOL Insight [2017]
    How will immunotherapy combination regimens impact the NSCLC treatment landscape?  The pace of change in NSCLC shows no sign of abating. Developments in immunotherapy continue to take centre stage, particularly in...
  • Bladder Cancer: KOL Insight [2017]
    Learn More Bladder Cancer: KOL Insight [2017]
    How will immune checkpoint inhibitors transform the treatment of Bladder Cancer? Significant progress has been made over the past decade in bladder cancer as a host of new targeted therapies have emerged from the...
  • Chronic Lymphocytic Leukaemia (CLL): KOL Insight [2017]
    Learn More Chronic Lymphocytic Leukaemia (CLL): KOL Insight [2017]
    Will novel targeted therapies establish a place in CLL treatment pathways?  Chemo-immunotherapy regimens incorporating Rituxan/MabThera have traditionally been at the forefront of CLL treatment. How is this all set...
  • Psoriasis: KOL Insight [2017]
    Learn More Psoriasis: KOL Insight [2017]
    Will biosimilar anti-TNFs prevent novel therapies from gaining traction?  As the use of biosimilar anti-TNFs continues to expand access , and lower the costs of, biologic therapies in the treatment for psoriasis,...
  • Renal Cell Carcinoma: KOL Insight [2017]
    Learn More Renal Cell Carcinoma: KOL Insight [2017]
    How will new combination regimens impact the RCC treatment landscape? The treatment of advanced RCC has been transformed in recent years as VEGF, TKI and mTOR inhibitors have taken centre stage. KOLs now argue that the...
  • Multiple Myeloma: KOL Insight [2017]
    Learn More Multiple Myeloma: KOL Insight [2017]
    Will novel therapies transform the treatment of Multiple Myeloma? In recent years, there has been significant progress in the prognosis for newly diagnosed multiple myeloma (MM) patients. While the current range of...
  • Systemic Lupus Erythematosus (SLE): KOL Insight
    Learn More Systemic Lupus Erythematosus (SLE): KOL Insight
    Will novel therapies revolutionise the treatment of SLE? With the approval of GSK’s Benlysta (belimumab) came the dawn of targeted therapy in the treatment of systemic lupus erythematosus (SLE). Roche’s...
  • CAR-T Therapy in Haematological Malignancy: Early Stage Outlook: KOL Insight [2017]
    Learn More CAR-T Therapy in Haematological Malignancy: Early Stage Outlook: KOL Insight [2017]
    Will CAR-T cell therapies shape the treatment of blood cancers in the next decade? Anti-CD19 CAR-T cell therapies have demonstrated unprecedented response rates across patient subgroups of acute lymphocytic leukaemia...
  • Nonalcoholic Steatohepatitis (NASH): KOL Insight [2017]
    Learn More Nonalcoholic Steatohepatitis (NASH): KOL Insight [2017]
    Will novel therapies revolutionise the treatment of NASH? No drug therapies have been approved for patients with nonalcoholic steatohepatitis (NASH) but how is this set to change within the next five years?...
  • Breast Cancer: KOL Insight [2017]
    Learn More Breast Cancer: KOL Insight [2017]
    How is Ibrance faring? Is Kisqali expected to be a threat? Having dominated the HER2-positive breast cancer space for many years, Roche’s blockbuster drug Herceptin is likely to face the threat of biosimilar...
  • Ovarian Cancer: KOL Insight [2017]
    Learn More Ovarian Cancer: KOL Insight [2017]
    How will new combination regimens impact the ovarian cancer treatment landscape? Competition is intensifying in the PARP inhibitor space due to the recent approval of Clovis’ Rubraca and Tesaro/Merck & Co...
  • COPD: KOL Insight [2017]
    Learn More COPD: KOL Insight [2017]
    Are closed triple combos expected to change treatment dynamics? New treatment guidelines look set to change the way in which COPD is treated. New guidelines from the Global Initiative for Chronic Obstructive Lung...
  • Rheumatoid Arthritis: KOL Insight [2017]
    Learn More Rheumatoid Arthritis: KOL Insight [2017]
    How are biosimilar anti-TNFs faring? Will your brand be affected? After several years on the US market, the availability of Pfizer’s Xeljanz in the EU is generally welcomed by KOLs; however, it now looks like Eli...
  • Head and Neck Squamous Cell Cancer: KOL Insight [2017]
    Learn More Head and Neck Squamous Cell Cancer: KOL Insight [2017]
    How will immunotherapy continue to shape the HNSCC treatment landscape? The availability of Merck &Co.’s Keytruda and BMS’ Opdivo has already transformed the second-line treatment of head and neck...
  • Cystic Fibrosis: KOL Insight [2017]
    Learn More Cystic Fibrosis: KOL Insight [2017]
    How will the novel CFTR-function restoring therapies impact the CF landscape? The arrival of Vertex’s Kalydeco and Orkambi was a major advance in the disease-modifying CF therapy. However, despite their...
  • Acute Myeloid Leukaemia (AML): KOL Insight [2017]
    Learn More Acute Myeloid Leukaemia (AML): KOL Insight [2017]
    Will novel targeted therapies change AML treatment pathways?  For decades, chemotherapies have been at the forefront of AML treatment. How is this all set to change within the next few years? Novartis’...

customer.service@firstwordpharma.com

All Contents Copyright © 2017 Doctor's Guide Publishing Limited All Rights Reserved